Atea Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen. Welcome to the ATIA Pharmaceuticals First Quarter 2021 Financial Results Conference Call. At this time, all participants are in the listen-only mode. Following the formal remarks, we will open the call-up for your questions. I would now like to turn the call over to Joan A. Barnes, Senior Vice President of Investor Relations and Corporate Communications of ATIA Pharmaceuticals. Please proceed.

Thank you, Operator. Good afternoon, everyone, and welcome to ATEA Pharmaceutical's first quarter 21 financial results conference call. Earlier today, we issued a press release which outlines the topics we plan to discuss. You can access the press release as well as the accompanying slides that we'll be reviewing today on the call by going to the Investors Relations section, then the Invent and Presentations area of our website at ir.com. AtteaPharma.com. With me today from Attea, our Founder, Chairman, and Chief Executive Officer, John Pierre Semedosi, Chief Development Officer, Janet Hammond, Chief Financial Officer and Executive Vice President of Legal, Andrea Corcoran, Chief Commercial Officer, John Bavrica, will also be available for the Q&A portion of today's call. On the call today, Jean-Pierre will provide a recap of our recent scientific publications and presentations for AT527. Janet will review our clinical progress for AT527 for the treatment of COVID-19 and AT752 for the treatment of dengue fever. Andrea will provide a financial update, and Jean-Pierre will review the upcoming milestones. Before we begin the call, I'd like to remind you that today's discussion will contain forward-looking statements that involve risk and uncertainties, as mentioned on slide two. These risks and uncertainties are outlined in today's press release and in the company's recent filings with the Securities and Exchange Commission, which we encourage you to read. Our actual results may differ materially from what is discussed on today's call. With that, I'll now turn the call over to Jean-Pierre.

Thank you, Joneigh. Good afternoon, everyone, and thank you for joining us today. We continue to make meaningful progress of our mission to discover and develop antiviral drugs for the treatment and prophylaxis of severe viral diseases. Our purine nucleotide prodrugs have pharmacological properties that are uniquely suited for the treatment and prevention of these viral diseases. Our drug candidates are designed to target viral RNA polymerase a highly conserved enzyme critical to the life cycle replication of these viruses. We believe our platform offers many advantages, including potent and selective antiviral activity, convenience of oral administration, and scalable manufacturing, all essential when targeting millions of patients worldwide. As we reported on our last conference call, we have been very active so far this year in publishing and presenting preclinical and clinical results for 8527. A recap of our scientific communications is on slide 3 and includes publishing a manuscript highlighting potent in vitro activity of 8527 against SARS-CoV-2 in antimicrobial agents and chemotherapy. We presented favorable Phase I results in March at the Conference on Retroviruses and Opportunistic Infections, or CROI. These results validate the modeling from our preclinical animal models, which predict that drug lung levels should consistently be above the EC90 level of 0.5 micromolar. Since the respiratory tract is the initiation site of the SARS-CoV-2 replication, These data demonstrate the potential for AT527 to achieve meaningful drug levels in the lungs. We were also invited to present supportive data on AT527 as a treatment for COVID-19 at the International Conference on Antiviral Research, or ICAR. The overview included phase one results as well as preclinical data and the underlying mechanistic rationale supporting In addition, we have worked very diligently to elucidate the dual mechanism of action of AT527 and the multi-modal and unique interactions with AT9010, the active triphosphate metabolite of AT527 against SARS-CoV RNA polymerase. A manuscript of this important data is currently in preprint on bioarchive and has been submitted for peer review. This growing body of preclinical and clinical evidence in support of our antiviral platform is compelling and encourages us to accelerate and expand our development pipeline in the very difficulty to treat viral diseases. Let me now turn the call over to Janet, who will review our clinical development programs. Janet?